MADISON, Wis., June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities. Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid – to help ensure they have the staffing needed to achieve patient treatment goals..

。根据协议条款，TrueNorth Medical Physics将提供与Accuray提供的服务互补和补充的服务，作为医院团队的延伸-现场、远程或混合-以帮助确保他们拥有实现患者治疗目标所需的人员。。

As the field of radiation medicine has evolved since the X-ray was discovered 125+ years ago, so too has the TrueNorth team which now has an equivalent number of combined clinical years of experience. They will leverage this vast knowledge base to provide physics, dosimetry and commissioning support for the Accuray TomoTherapy®, Radixact® and CyberKnife® Systems.

自从125多年前X射线被发现以来，放射医学领域发生了变化，TrueNorth团队也发生了变化，现在他们拥有相当数量的临床经验。。

TrueNorth offers specialized services that help augment a hospital's team and are tailored to their specific requirements. From providing additional staff while the site recruits new personnel or when only part-time assistance is desired, to sharing expertise that facilitates adoption of new technology and techniques, the company is equipped to meet these needs..

TrueNorth提供专业服务，有助于增强医院的团队，并根据其具体需求量身定制。。。

'We are excited about the opportunity to partner with Accuray and assist their customers. We have extensive experience working with Accuray's Radixact, TomoTherapy and CyberKnife platforms and are impressed with the unique features and associated benefits they provide,' said Matt Daniels, Ph.D., DABR, one of the TrueNorth Managing Partners.

“我们很高兴有机会与Accuray合作并帮助他们的客户。TrueNorth管理合伙人之一、DABR博士马特·丹尼尔斯（MattDaniels）说，我们在使用Accuray的Radixact、TomoTherapy和CyberKnife平台方面拥有丰富的经验，并对它们提供的独特功能和相关好处印象深刻。

'Nevertheless, we are an independent company with expertise across multiple industry platforms. Our organization is dedicated to providing unbiased feedback and support that improves the practice of radiation therapy medicine and enhances a team's ability to deliver care.'.

“然而，我们是一家独立的公司，拥有跨多个行业平台的专业知识。我们的组织致力于提供无偏见的反馈和支持，以改善放射治疗医学的实践，提高团队提供护理的能力。”。

The addition of the TrueNorth offerings signifies a commitment from Accuray to provide an expanded range of solutions to help empower medical professionals from day one and throughout their tenure using the company's technology. The assistance they require will vary based on their clinical and economic goals, experience, and equipment age.

TrueNorth产品的增加意味着Accuray承诺提供更广泛的解决方案，以帮助医疗专业人员从第一天开始以及在整个任期内使用公司的技术。他们需要的援助将根据他们的临床和经济目标，经验和设备年龄而有所不同。

Accuray offers a combination of standard and customizable services to align with differing preferences and circumstances, aimed at helping clinicians to deliver the best possible outcomes for patients..

Accuray提供标准和可定制服务的组合，以适应不同的偏好和情况，旨在帮助临床医生为患者提供最佳的结果。。

'Accuray is committed to innovation in every aspect of our business, whether it be the radiotherapy technology we develop or the support we provide to customers to help them achieve their patient-focused treatment objectives,' said Suzanne Winter, president and CEO of Accuray. 'In today's dynamic and evolving healthcare environment, labor shortages and operational challenges may hinder hospitals from maintaining the staffing levels needed to meet their clinical demands and standards. We partnered with TrueNorth Medical Physics to provide care teams with another option for obtaining the resources they require to advance the treatment of cancer for more patients within their facilities.'.

Accuray总裁兼首席执行官苏珊娜·温特（SuzanneWinter）说：“Accuray致力于在业务的各个方面进行创新，无论是我们开发的放射治疗技术，还是我们为客户提供的支持，以帮助他们实现以患者为中心的治疗目标。”在当今动态变化的医疗环境中，劳动力短缺和运营挑战可能会阻碍医院维持满足临床需求和标准所需的人员配置水平。我们与TrueNorth Medical Physics合作，为护理团队提供另一种选择，以获得他们所需的资源，从而为其设施内的更多患者推进癌症治疗。”。

About AccurayAccuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs.

关于AccurayAccuray致力于扩大放射治疗的强大潜力，以尽可能多地改善生活。我们发明了独特的，改变市场的解决方案，旨在为最复杂的病例提供放射治疗，同时使通常可治疗的病例更容易满足患者的全部需求。

We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube..

我们与临床医生和管理人员合作，致力于肿瘤放射治疗、神经放射外科等领域的不断创新，使他们能够帮助患者更快地恢复生活。Accuray总部位于威斯康星州麦迪逊，在全球拥有设施。要了解更多信息，请访问www.accuray.com或在Facebook、LinkedIn、Twitter和YouTube上关注我们。。

Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the offerings provided by TrueNorth and the partnership with TrueNorth.

安全港声明本新闻稿中不属于历史事实声明的声明是前瞻性声明，受1995年《私人证券诉讼改革法》中“安全港”规定的约束。本新闻稿中的前瞻性声明涉及但不限于对TrueNorth提供的产品以及与TrueNorth的合作关系的期望。

These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products and offerings; the company's ability to develop new products and offerings or improve existing products and offerings to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading 'Risk Factors' in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the 'SEC') on May 8, 2024, and as updated periodically with the company's other filings with the SEC..

这些风险和不确定性包括但不限于当前全球经济环境（包括新型冠状病毒肺炎大流行）对公司及其客户和供应商运营的影响；公司产品和服务获得广泛市场认可的能力；公司开发新产品和服务或改进现有产品和服务以满足客户需求的能力；公司预测或跟上市场变化、技术创新方向和客户需求的能力；依赖第三方合作者、合作伙伴、战略联盟和合资企业；以及2024年5月8日提交给美国证券交易委员会（“SEC”）的公司季度报告中“风险因素”标题下确定的其他风险，并随公司提交给SEC的其他文件定期更新。。

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

前瞻性声明仅在声明发布之日有效，并且是基于公司发布这些声明时可用的信息和/或管理层当时对未来事件的诚信信念。本公司不承担更新前瞻性报表以反映实际业绩或结果、假设变化或影响前瞻性信息的其他因素变化的义务，适用证券法要求的除外。

Accordingly, investors should not put undue reliance on any forward-looking statements..

因此，投资者不应过度依赖任何前瞻性声明。。

Media ContactBeth KaplanPublic Relations Director, AccurayPhone +1 (408) 789-4426Email: bkaplan@accuray.com

媒体联系人Beth Kaplan AccurayPhone公共关系总监+1（408）789-4426电子邮件：bkaplan@accuray.com

SOURCE Accuray Incorporated

SOURCE Accuray公司